Theriva repurchases 720k shares from subsidiary founders at $0.4001/share for $288k

Theriva Biologics, Inc.

Repurchased 720,000 shares from three founders (Manel Maria Cascallo Piqueras, Ramon Alemany, Gabriel Maria Capella Minar) at $0.4001 per share.
Aggregate purchase price of $288,072; funded from cash on hand; shares will be held as treasury stock.
Selling stockholders originally acquired shares as consideration for sale of subsidiary to Theriva in March 2022.
Transaction privately negotiated; not part of a broader buyback program.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Theriva Biologics, Inc. entered into Share Repurchase Agreement with Manel Maria Cascallo Piqueras, Ramon Alemany and Gabriel Maria Capella Minar valued at $288,072 (effective 2022-12-20).

Action: entry
Agreement: equity purchase
Counterparty: Manel Maria Cascallo Piqueras, Ramon Alemany and Gabriel Maria Capella Minar
Value: $288,072
Effective: 2022-12-20

Exact text from the filing

On December 22, 2022, Theriva Biologics, Inc. (the “Company”) repurchased an aggregate of 720,000 shares of its common stock, par value $0.0001 (the “Common Stock”) from Manel Maria Cascallo Piqueras, Ramon Alemany and Gabriel Maria Capella Minar (the “Selling Stockholders”), three founders of its subsidiary Theriva Biosciences S.L. (formerly known as VCN Biosciences S.L.) in a privately negotiated transaction pursuant to the terms of a Share Repurchase Agreement entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) entered into on December 20, 2022 with each of the Selling Stockholders. The price per share was $0.4001, which was the closing price of the Common Stock on the day prior to the closing for an aggregate purchase price was $288,072.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-129900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.